Quinine is a more potent inhibitor than quinidine in rat of the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase.

1. Lewis rats (n = 7 or 8) were dosed with methoxyphenamine with and without prior administration of various doses of either quinine or its diastereomer quinidine. Methoxyphenamine and its N-desmethyl, O-desmethyl and aromatic 5-hydroxy metabolites were quantified in 0-24 h urine. 2. The oxidative routes of methoxyphenamine metabolism which had been previously shown to involve the debrisoquine/sparteine isoenzyme, namely O-demethylation and 5-hydroxylation, were both significantly inhibited by quinine. The inhibition was selective in that N-demethylation which does not involve this isoenzyme was not affected by quinine. 3. Quinidine which had been previously shown at a relatively high dose (80 mg/kg) to affect the three metabolic routes of methoxyphenamine in a similar fashion was ineffective in this regard at a 25 mg/kg dose. Quinine more effectively inhibited the O-demethylation and 5-hydroxylation of methoxyphenamine than did quinidine, and its inhibition was marked at the lowest dose examined, 12.5 mg/kg. 4. As quinidine is a more potent inhibitor than quinine of debrisoquine 4-hydroxylase in man, the rat should be used only with full realization of its limitations when investigating substrates metabolized by this isoenzyme.

[1]  K. Brøsen,et al.  A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. , 1990, British journal of clinical pharmacology.

[2]  A. Boobis,et al.  The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. , 1989, Biochemical pharmacology.

[3]  K. Midha,et al.  Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism. , 1989, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  R. Dahlqvist,et al.  Inhibition of desipramine 2‐hydroxylation by quinidine and quinine , 1988, Clinical pharmacology and therapeutics.

[5]  K. Midha,et al.  Influence of urinary pH on the disposition of methoxyphenamine and three metabolites in humans. , 1987, Journal of pharmaceutical sciences.

[6]  C. Kozak,et al.  Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. , 1987, DNA.

[7]  K. Midha,et al.  Methoxyphenamine O-demethylase and 5-hydroxylase: a GLC-ECD assay to study their activities and their inhibition by debrisoquine and sparteine. , 1987, Pharmacology & therapeutics.

[8]  A. Boobis,et al.  Bufuralol 1'-hydroxylase activity of the rat. Strain differences and the effects of inhibitors. , 1986, Biochemical pharmacology.

[9]  T. Yoshida,et al.  Studies on the mechanism of interaction between methamphetamine and quinine in rats. , 1986, Journal of Pharmacobio-Dynamics.

[10]  G McKay,et al.  Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin , 1985, Clinical pharmacology and therapeutics.

[11]  T. Henthorn,et al.  Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. , 1985, Biochemical pharmacology.

[12]  W. Kalow,et al.  In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[13]  K. Midha,et al.  Methoxyphenamine metabolism in rat models of human debrisoquine phenotypes. , 1985, Canadian journal of physiology and pharmacology.

[14]  F. Guengerich,et al.  Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. , 1984, Biochemistry.

[15]  W. Kalow,et al.  Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. , 1984, Life sciences.

[16]  K. Midha,et al.  Identification of new secondary metabolites of methoxyphenamine in man. , 1983, Xenobiotica; the fate of foreign compounds in biological systems.

[17]  J. Idle,et al.  Animal modelling of human polymorphic drug oxidation—the metabolism of debrisoquine and phenacetin in rat inbred strains , 1981, The Journal of pharmacy and pharmacology.